RaySearch Laboratories AB (publ) carries a market capitalization of 822.79M, placing it among publicly traded companies globally. Its enterprise value stands at 6.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 822.79M |
| Enterprise Value | 6.76B |
RaySearch Laboratories AB (publ) currently has 34.28M shares outstanding.
| Shares Outstanding | 34.28M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
RaySearch Laboratories AB (publ) trades at a trailing price-to-earnings ratio of 30.43.
| PE Ratio | 30.43 |
| PS Ratio | 5.24 |
| PB Ratio | N/A |
| P/TBV Ratio | 14.63 |
| P/FCF Ratio | 18.10 |
| P/OCF Ratio | 19.54 |
On an enterprise value basis, RaySearch Laboratories AB (publ) trades at an EV/EBITDA multiple of 23.72 and an EV/FCF ratio of 17.93. The EV/Sales ratio of 5.19 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 23.72 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.19 |
| EV / EBITDA | 23.72 |
| EV / EBIT | 23.72 |
| EV / FCF | 17.93 |
RaySearch Laboratories AB (publ) maintains a current ratio of 1.79, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.79 |
| Quick Ratio | 0.78 |
| Debt / Equity | 36.18 |
| Debt / EBITDA | 1.32 |
| Interest Coverage | N/A |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 10.97 |
| Return on Invested Capital (ROIC) | 16.07 |
| Return on Capital Employed (ROCE) | 54.23 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.30 |
Over the trailing twelve months, RaySearch Laboratories AB (publ) has paid 60.51M in income taxes, reflecting an effective tax rate of 21.28.
| Income Tax | 60.51M |
| Effective Tax Rate | 21.28 |
RaySearch Laboratories AB (publ)'s stock has declined approximately -25.44268% over the past 52 weeks. The 50-day moving average sits at 23.16, while the 200-day moving average is 25.49.
| Beta (5Y) | N/A |
| 52-Week Price Change | -25.44268% |
| 50-Day Moving Average | 23.16 |
| 200-Day Moving Average | 25.49 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, RaySearch Laboratories AB (publ) generated 1.30B in revenue and converted that into 224.16M in net income, yielding earnings per share of 6.53. EBITDA reached 284.96M, while operating income came in at 284.96M.
| Revenue | 1.30B |
| Gross Profit | 1.20B |
| Operating Income | 284.96M |
| Pretax Income | 284.27M |
| Net Income | 224.16M |
| EBITDA | 284.96M |
| EBIT | 284.96M |
| Earnings Per Share (EPS) | 6.53 |
RaySearch Laboratories AB (publ) holds 439.30M in cash and equivalents against 377.30M in total debt, resulting in a net debt position of -439.30M.
| Cash & Cash Equivalents | 439.30M |
| Total Debt | 377.30M |
| Net Debt | -439.30M |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | 446.20M |
RaySearch Laboratories AB (publ) produced 349.08M in operating cash flow over the past twelve months. After subtracting -27.91M in capital expenditures, free cash flow totaled 321.17M - equivalent to 9.38 per share.
| Operating Cash Flow | 349.08M |
| Capital Expenditures | -27.91M |
| Free Cash Flow | 321.17M |
| FCF Per Share | 9.38 |
RaySearch Laboratories AB (publ) operates with a gross margin of 92.45, reflecting its pricing power and cost economics. The operating margin of 21.87 and net profit margin of 17.21 provide insight into operational efficiency.
| Gross Margin | 92.45 |
| Operating Margin | 21.87 |
| Pretax Margin | 21.82 |
| Profit Margin | 17.21 |
| EBITDA Margin | 21.87 |
The company's payout ratio of 45.96 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 3.00 |
| Dividend Yield | N/A |
| Payout Ratio | 45.96 |
| Shareholder Yield | 2.63 |
| FCF Yield | 5.53 |
RaySearch Laboratories AB (publ) posts an Altman Z-Score of 6.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.07 |